KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Profit After Tax (2016 - 2025)

Emergent BioSolutions' Profit After Tax history spans 15 years, with the latest figure at -$54.6 million for Q4 2025.

  • For Q4 2025, Profit After Tax fell 74.44% year-over-year to -$54.6 million; the TTM value through Dec 2025 reached $52.6 million, up 127.6%, while the annual FY2025 figure was $52.6 million, 127.6% up from the prior year.
  • Profit After Tax reached -$54.6 million in Q4 2025 per EBS's latest filing, down from $51.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $193.1 million in Q4 2021 to a low of -$283.1 million in Q2 2024.
  • Average Profit After Tax over 5 years is -$44.5 million, with a median of -$35.8 million recorded in 2021.
  • Peak YoY movement for Profit After Tax: plummeted 10480.0% in 2022, then surged 655.56% in 2025.
  • A 5-year view of Profit After Tax shows it stood at $193.1 million in 2021, then plummeted by 134.7% to -$67.0 million in 2022, then increased by 26.12% to -$49.5 million in 2023, then surged by 36.77% to -$31.3 million in 2024, then tumbled by 74.44% to -$54.6 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Profit After Tax are -$54.6 million (Q4 2025), $51.2 million (Q3 2025), and -$12.0 million (Q2 2025).